Promotion of Saxenda by Med Connections Limited (trading as Doctor 4 U)
Published 9 June 2021
漏 Crown copyright 2021
This publication is licensed under the terms of the Open Government Licence v3.0 except where otherwise stated. To view this licence, visit or write to the Information Policy Team, 皇冠体育app National Archives, Kew, London TW9 4DU, or email: [email protected].
Where we have identified any third party copyright information you will need to obtain permission from the copyright holders concerned.
This publication is available at /government/publications/advertising-investigations-february-2021/promotion-of-saxenda-by-med-connections-limited-trading-as-doctor-4-u
SUMMARY REPORT FOR PUBLICATION
February 2021 Promotion of Saxenda by Med Connections Limited (trading as Doctor 4 U)
皇冠体育app MHRA received 2 complaints concerning an advertisement for liraglutide (Saxenda, a prescription medicine licensed to help manage weight in eligible adults) which was proactively distributed via email by Doctor 4 U. 皇冠体育app complainants alleged that the email advertising campaign did not comply with the Regulations because it promoted a prescription only medicine to the public.
皇冠体育app MHRA upheld the complaint. Doctor 4 U confirmed that they corrected an error in a software tool that had incorrectly classified the medicine as P (Pharmacy) legal status, which led to the distribution of the email to consumers. 皇冠体育app company confirmed that they had implemented corrective measures including internal training and a sign-off process to ensure a clinician approves advertising copy before release to consumer contacts.